BlackRock (NYSE: BLK) discloses 16.6M-share Sarepta Therapeutics (SRPT) position in 13G/A

Rhea-AI Filing Summary

BlackRock, Inc. reports significant ownership in Sarepta Therapeutics Inc common stock under an amended Schedule 13G. BlackRock and certain of its reporting business units beneficially own 16,642,620 shares of Sarepta common stock, representing 15.8% of the outstanding class as of the reporting date.

BlackRock has sole voting power over 16,353,161 shares and sole dispositive power over 16,642,620 shares, with no shared voting or dispositive power reported. The filing notes that one holder, iShares Core S&P Small-Cap ETF, has an interest in more than five percent of Sarepta’s outstanding common stock. The disclosure reflects only securities held by specified BlackRock business units, excluding those disaggregated under SEC Release No. 34-39538.

Key Figures

Beneficially owned shares: 16,642,620 shares Ownership percentage: 15.8% Sole voting power: 16,353,161 shares +4 more

7 metrics

Beneficially owned shares 16,642,620 shares Shares of Sarepta Therapeutics common stock beneficially owned by BlackRock reporting units

Ownership percentage 15.8% Percent of Sarepta Therapeutics common stock class beneficially owned

Sole voting power 16,353,161 shares Shares over which BlackRock has sole power to vote or direct the vote

Shared voting power 0 shares Shares over which BlackRock has shared power to vote

Sole dispositive power 16,642,620 shares Shares over which BlackRock has sole power to dispose or direct disposition

Shared dispositive power 0 shares Shares over which BlackRock has shared power to dispose

Reporting date 06/30/2026 Date as of which the ownership information is reported

Key Terms

beneficially owned, sole voting power, sole dispositive power, Schedule 13G, +1 more

5 terms

beneficially owned financial

"this reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole Voting Power 16,353,161.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole Dispositive Power 16,642,620.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G regulatory

"If a parent holding company has filed this schedule, pursuant to (ii)(G), so indicate under Item 3(g)"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/30/2026 - 11:19 AM Accepted by SEC EDGAR 07/30/2026 - 11:18 AM Learn about SEC filing dates

FAQ

How many Sarepta Therapeutics (SRPT) shares does BlackRock report owning?

BlackRock reports 16,642,620 shares of Sarepta Therapeutics common stock as beneficially owned. This position is disclosed by certain BlackRock business units under Schedule 13G/A and reflects holdings as of the reported date.

What percentage of Sarepta Therapeutics (SRPT) does BlackRock beneficially own?

BlackRock reports beneficial ownership of 15.8% of Sarepta Therapeutics’ common stock. This percentage is based on the company’s total outstanding shares and is stated explicitly in the ownership section.

What voting power does BlackRock have over its Sarepta Therapeutics (SRPT) shares?

BlackRock has sole voting power over 16,353,161 shares of Sarepta common stock and reports no shared voting power. It also reports sole dispositive power over all 16,642,620 beneficially owned shares.

Does any BlackRock-related fund hold more than 5% of Sarepta Therapeutics (SRPT)?

Yes. The filing states that iShares Core S&P Small-Cap ETF has an interest in more than 5% of Sarepta’s total outstanding common stock. This ETF is identified under the item covering ownership on behalf of another person.

What is the nature of BlackRock’s dispositive power over Sarepta Therapeutics (SRPT) shares?

BlackRock reports sole dispositive power over 16,642,620 shares of Sarepta common stock and no shared dispositive power. This means the reporting business units can direct the disposition of these shares without shared authority.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 12)

SAREPTA THERAPEUTICS INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

803607100

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 803607100

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 16,353,161.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 16,642,620.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

16,642,620.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.8 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: SAREPTA THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 803607100
Item 4.	Ownership
(a)	Amount beneficially owned: 16642620
(b)	Percent of class: 15.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 16353161
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 16642620
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The interest of 1 such person, iShares Core S&P Small-Cap ETF, in the common stock of SAREPTA THERAPEUTICS INC is more than five percent of the total outstanding common stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	07/30/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7